PCA
AST

Providence Capital Advisors’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Providence Capital Advisors’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12
Closed – – 267
2018
Q1 		$0 Hold
12
– – ﹤0.01% 322
2017
Q4 		$0 Buy
+12
New +$30 ﹤0.01% 312

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Providence Capital Advisors's AST Position: Q2 2018 in Review

Providence Capital Advisors sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2018, closing a stake of 12 shares.

Providence Capital Advisors first reported a position in AST in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q1 2018. 62 funds tracked by Wall St. Rank hold AST as of Q2 2018.

  • Providence Capital Advisors reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2018 after selling out during the quarter.
  • Providence Capital Advisors sold 12 Asterias Biotherapeutics Inc. Series A shares in Q2 2018.
  • Providence Capital Advisors first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2017 and held it in 2 quarters.
  • Providence Capital Advisors's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q1 2018.
  • 62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2018.

Based on Providence Capital Advisors's 13F filing for Q2 2018, filed 8 Aug 2018.